SCHEMBL3149648

SCHEMBL3149648

CCC(C)[C@H](C(=O)O)N(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
MME P08473 2/20 0.38
ACE P12821 2/20 0.38
CPA1 P15085 2/20 0.38
ACE2 Q9BYF1 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.34
CHRNB2 P17787 6/20 0.33
CHRNA4 P43681 6/20 0.33
CHRNB4 P30926 5/20 0.33
TP53 P04637 1/20 0.33
GRIN2D O15399 2/20 0.33
GRIN1 Q05586 2/20 0.33
GRIN2A Q12879 2/20 0.33
GRIN2B Q13224 2/20 0.33
GRIN2C Q14957 2/20 0.33
OPRM1 P35372 2/20 0.33
CACNA1F O60840 1/20 0.33
ABCB1 P08183 1/20 0.33
CYP2B6 P20813 1/20 0.33
DRD4 P21917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14889910 1.00 ALDH1A1 (0.39) ALDH1A1MMEACECPA1ACE2
SCHEMBL3527314 1.00 ALDH1A1 (0.39) ALDH1A1MMEACECPA1ACE2
SCHEMBL196729 1.00 ALDH1A1 (0.39) ALDH1A1MMEACECPA1ACE2
SCHEMBL196730 1.00 ALDH1A1 (0.39) ALDH1A1MMEACECPA1ACE2
SCHEMBL17772985 0.84 ALDH1A1 (0.38) ALDH1A1MMEACECPA1ACE2
SCHEMBL3154732 0.82 ALDH1A1 (0.37) ALDH1A1MMEACECPA1ACE2
SCHEMBL8708558 0.82 ALDH1A1 (0.37) ALDH1A1MMEACECPA1ACE2
SCHEMBL3156914 0.82 ALDH1A1 (0.37) ALDH1A1MMEACECPA1ACE2
SCHEMBL28389417 0.82 ALDH1A1 (0.37) ALDH1A1MMEACECPA1ACE2
SCHEMBL3154725 0.82 ALDH1A1 (0.37) ALDH1A1MMEACECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100076015-A1 Aminopyridine Derivatives VANTIA LIMITED (GB) 2010-03-25 US claimed
WO-2009133348-A1 AMINOPYRIDINE DERIVATIVES VANTIA LIMITED (GB) 2009-11-05 WO claimed
US-20100076015-A1 Aminopyridine Derivatives VANTIA LIMITED (GB) 2010-03-25 US disclosed
WO-2009133348-A1 AMINOPYRIDINE DERIVATIVES VANTIA LIMITED (GB) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076015-A1 Aminopyridine Derivatives CHRM1, ARG1, ARG2 ALDH1A1 147/4885MME 4329/4885ACE 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.